Ryeqo (Relugolix compound tablets) - long-term treatment for uterine fibroids

(Relugolix compound tablets) was developed by Takeda Pharmaceutical Company and was approved by PMDA to be launched in Japan on January 8, 2019. Its trade name is Relumina (40 mg tablets), which is used to improve symptoms such as menorrhagia, lower abdominal pain, low back pain and anemia caused by uterine fibroids. Afterwards, the drug was submitted by Myovant Sciences and approved by the FDA for marketing in the United States on December 18, 2020. Its trade name is Orgovyx (120 mg tablet) for the treatment of advanced prostate cancer in adults. Subsequently, on May 26, 2021, the compound preparation of the drug (40 mg of this product, 1.0 mg of estradiol, 0.5 mg of norethindrone acetate) was jointly submitted by Pfizer and Myovant Sciences, and was approved by the FDA on May 26, 2021. Its trade name is Myfembree, which is used to treat female uterine fibroids.

Instructions: Take one tablet orally daily with or without food. When starting treatment, the first tablet must be taken within 5 days of menstrual bleeding. Common side effects of this drug are increased sweating, lumps in the breast tissue (breast cysts), hair loss, decreased interest in sex, irritability, indigestion, night sweats, hot flashes, excessive, irregular or persistent bleeding from the uterus (uterine bleeding), and more.

Finally, the editor of Medical Companion Travel would like to remind patients who are currently using Ryeqo that there has been a lot of loose news recently saying that if patients feel that the effect of the drug is not good, they can increase the dose of the drug, or that the dose of the drug can be reduced if the side effects are too great during the medication. These are all without scientific basis. Only by carefully following the doctor's instructions can the effect of the drug itself be maximized.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.